$IONS News

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Ionis ranked #1 on Science’s Top Employers list

Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment

BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

Ionis Pharmaceuticals Receives EMA CHMP Positive Opinion Recommending Indication Extension For TRYNGOLZA For Treatment Of Adult Patients With Severe Hypertriglyceridemia

Ionis Pharmaceuticals (IONS) After The Pullback Is The Undervalued Narrative Still Intact

Ionis Pharmaceuticals (IONS) Stock Could Still Trade At A Premium Despite A 46% Slump

Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide

HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

Roche, Ionis RNA drug scores in kidney disease study

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease

Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks

Ionis to Seek Expedited FDA Review for ALS Drug

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS